Integra LifeSciences (NASDAQ:IART) Trading Up 8.4% – Here’s Why

Shares of Integra LifeSciences Holdings Corporation (NASDAQ:IART) rose 8.4% during mid-day trading on Monday . The stock traded as high as $17.89 and last traded at $18.0450. Approximately 61,001 shares were traded during mid-day trading, a decline of 93% from the average daily volume of 907,707 shares. The stock had previously closed at $16.65.

Wall Street Analyst Weigh In

A number of research firms have commented on IART. BMO Capital Markets initiated coverage on Integra LifeSciences in a report on Wednesday, July 8th. They issued a “market perform” rating and a $19.00 target price for the company. Weiss Ratings downgraded Integra LifeSciences from a “sell (d-)” rating to a “sell (e+)” rating in a report on Thursday, July 30th. Citigroup reaffirmed a “neutral” rating and set a $19.00 price objective (up from $16.00) on shares of Integra LifeSciences in a research report on Wednesday, July 8th. Argus upgraded Integra LifeSciences from a “hold” rating to a “buy” rating and set a $25.00 price objective for the company in a report on Thursday, June 18th. Finally, UBS Group began coverage on Integra LifeSciences in a research report on Tuesday, July 28th. They issued a “neutral” rating and a $19.00 target price for the company. One analyst has rated the stock with a Buy rating, five have assigned a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of “Reduce” and a consensus target price of $18.86.

Integra LifeSciences Price Performance

The company has a current ratio of 3.60, a quick ratio of 2.11 and a debt-to-equity ratio of 1.75. The stock has a market capitalization of $1.39 billion, a PE ratio of -198.87, a price-to-earnings-growth ratio of 1.51 and a beta of 1.21. The firm has a 50 day moving average price of $17.81 and a 200 day moving average price of $13.55.

Integra LifeSciences (NASDAQ:IART) last released its earnings results on Wednesday, July 29th. The life sciences company reported $0.56 earnings per share for the quarter, beating the consensus estimate of $0.48 by $0.08. Integra LifeSciences had a positive return on equity of 18.30% and a negative net margin of 0.44%.The company had revenue of $418.76 million for the quarter, compared to the consensus estimate of $417.54 million. Integra LifeSciences has set its Q3 2026 guidance at 0.530-0.610 EPS and its FY 2026 guidance at 2.400-2.500 EPS. Research analysts anticipate that Integra LifeSciences Holdings Corporation will post 2.46 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in IART. Hsbc Holdings PLC bought a new stake in Integra LifeSciences during the 4th quarter worth approximately $879,000. Tejara Capital Ltd boosted its position in shares of Integra LifeSciences by 42.6% in the fourth quarter. Tejara Capital Ltd now owns 171,813 shares of the life sciences company’s stock worth $2,134,000 after purchasing an additional 51,300 shares during the period. Glenmede Trust Co. NA boosted its position in shares of Integra LifeSciences by 27.4% in the first quarter. Glenmede Trust Co. NA now owns 984,686 shares of the life sciences company’s stock worth $9,276,000 after purchasing an additional 211,774 shares during the period. Paradigm Capital Management Inc. NY increased its stake in shares of Integra LifeSciences by 50.6% in the first quarter. Paradigm Capital Management Inc. NY now owns 4,012,698 shares of the life sciences company’s stock worth $37,800,000 after purchasing an additional 1,347,700 shares in the last quarter. Finally, Systematic Financial Management LP raised its position in shares of Integra LifeSciences by 4.5% during the 4th quarter. Systematic Financial Management LP now owns 1,108,599 shares of the life sciences company’s stock valued at $13,769,000 after purchasing an additional 48,094 shares during the period. 84.78% of the stock is currently owned by institutional investors.

About Integra LifeSciences

Integra LifeSciences Corporation is a global medical technology company specializing in products and innovations for neurosurgery, regenerative medicine and reconstructive procedures. The company develops and markets surgical instruments, implants and advanced wound care solutions designed to support tissue repair and functional recovery. Its product portfolio includes collagen-based matrices, dural substitutes, hemostatic agents and specialized spinal and peripheral fixation devices.

Founded in 1989 and headquartered in Plainsboro, New Jersey, Integra has expanded its capabilities through targeted acquisitions and internal research efforts.